Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?

Buwalda B, Schagen SB.

Life Sci. 2013 Oct 17;93(17):581-8. doi: 10.1016/j.lfs.2012.12.012. Epub 2013 Jan 23. Review.

PMID:
23353876
2.

Vascular effects of aromatase inhibitors: data from clinical trials.

Howell A, Cuzick J.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):143-9. Erratum in: J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):180.

PMID:
15936188
3.

Cognitive changes associated with endocrine therapy for breast cancer.

Agrawal K, Onami S, Mortimer JE, Pal SK.

Maturitas. 2010 Nov;67(3):209-14. doi: 10.1016/j.maturitas.2010.07.004. Epub 2010 Aug 4.

4.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
5.

Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.

Baumann CK, Castiglione-Gertsch M.

Minerva Ginecol. 2009 Dec;61(6):517-39. Review.

PMID:
19942839
6.

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.

J Clin Oncol. 2010 Mar 10;28(8):1294-300. doi: 10.1200/JCO.2008.21.3553. Epub 2010 Feb 8.

7.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
8.

Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.

Breckenridge LM, Bruns GL, Todd BL, Feuerstein M.

Psychooncology. 2012 Jan;21(1):43-53. doi: 10.1002/pon.1860. Epub 2010 Oct 21.

PMID:
20967847
9.

[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].

de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY.

Bull Cancer. 2004 Dec;91(12):917-27. Review. French.

PMID:
15634633
10.

Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.

Schilder CM, Schagen SB.

Minerva Ginecol. 2007 Aug;59(4):387-401. Review.

PMID:
17923830
11.

Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.

Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W, Berstein L.

Endocr Relat Cancer. 2003 Jun;10(2):111-30. Review.

12.

Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.

Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA.

J Clin Exp Neuropsychol. 2004 Oct;26(7):955-69.

PMID:
15742545
13.

[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].

Tuxen MK, Nielsen DL, Lindberg H, Kamby C.

Ugeskr Laeger. 2007 Jan 22;169(4):297-9. Review. Danish.

PMID:
17274922
14.

[Specific estrogen receptor modulators (SERMs)].

Trémollières F, Lopes P.

Presse Med. 2002 Sep 7;31(28):1323-8. Review. French.

PMID:
12355995
15.

Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

Baumann CK, Castiglione-Gertsch M.

Drugs. 2007;67(16):2335-53. Review.

PMID:
17983255
16.

The influence of endocrine treatments for breast cancer on health-related quality of life.

Buijs C, de Vries EG, Mourits MJ, Willemse PH.

Cancer Treat Rev. 2008 Nov;34(7):640-55. doi: 10.1016/j.ctrv.2008.04.001. Epub 2008 Jun 2. Review.

PMID:
18514425
17.

Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments.

Vodermaier A.

Womens Health (Lond Engl). 2009 Sep;5(5):503-16. doi: 10.2217/whe.09.36. Review.

PMID:
19702450
18.

Adherence to long-term adjuvant hormonal therapy for breast cancer.

Gotay C, Dunn J.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-15. doi: 10.1586/erp.11.80. Review.

PMID:
22098287
19.

Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.

Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K.

Cancer. 2008 Nov 1;113(9):2431-9. doi: 10.1002/cncr.23853.

Items per page

Supplemental Content

Write to the Help Desk